Skip to content
Subscribe Follow on LinkedIn

Latest

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

✨ Onyx Summary Seer, Inc. announced publication in Nature Genetics of a large-scale GWAS demonstrating that its Proteograph platform’s peptide-level mass spectrometry is critical for accurately validating protein–gene associations and reducing false signals common in affinity-based proteomics. The study, spanning ~1,600 multi-ethnic samples, shows that up to one-third

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

✨ Onyx Summary Rocket Pharmaceuticals announced that CEO Dr. Gaurav Shah will participate in a fireside chat and investor meetings at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The appearance provides a platform to engage investors on Rocket’s late-stage gene therapy pipeline and strategic priorities as it

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

✨ Onyx Summary Lexicon Pharmaceuticals announced that company management will participate in fireside chats at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the Evercore 8th Annual Healthcare Conference on December 4, 2025, with live and replay access available through the company’s investor website. THE WOODLANDS,

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

✨ Onyx Summary enGene Holdings Inc. announced that Chief Strategy and Operations Officer Alex Nichols, Ph.D., will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with a webcast available via the company’s investor website. BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene”

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

✨ Onyx Summary Foghorn Therapeutics announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025, with a webcast available via the company’s investor website. CAMBRIDGE, Mass., Nov. 25, 2025 – Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a

Keros Therapeutics Announces Final Results of Tender Offer

Keros Therapeutics Announces Final Results of Tender Offer

✨ Onyx Summary Keros Therapeutics, Inc. announced the final results of its cash tender offer, repurchasing 10.95 million shares at $17.75 per share for approximately $194.4 million, representing about 35.9% of outstanding shares. The oversubscribed tender, which applied a final proration factor of roughly 62.3%, concludes

Perspective Therapeutics to Participate in Upcoming December Conferences

Perspective Therapeutics to Participate in Upcoming December Conferences

✨ Onyx Summary Perspective Therapeutics announced that members of its senior leadership team will participate in fireside chats and investor meetings at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore 8th Annual Healthcare Conference on December 3, 2025. SEATTLE, Nov. 20, 2025 – November 20, 2025

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

✨ Onyx Summary Avidity Biosciences launched an FDA-authorized Managed Access Program in the United States to provide investigational delpacibart zotadirsen to eligible patients with Duchenne muscular dystrophy amenable to exon 44 skipping, addressing a population with no approved exon-skipping therapies. The program aligns with Avidity’s planned 2026 BLA submission for

Keros Therapeutics Announces Preliminary Results of Tender Offer

Keros Therapeutics Announces Preliminary Results of Tender Offer

✨ Onyx Summary Keros Therapeutics, Inc. announced preliminary results of its cash tender offer, expecting to repurchase 10.95 million shares at $17.75 per share for approximately $194.4 million, representing about 35.9% of outstanding shares. The oversubscribed tender concludes Keros’ previously announced $375 million capital return program, materially

Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025

Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025

✨ Onyx Summary Alzheon, Inc. announced it will present new long-term efficacy, safety, and quantitative systems pharmacology data for its oral Alzheimer’s therapy valiltramiprosate (ALZ-801) at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference in December 2025. The presentations will highlight three-year Phase 2 extension results and modeling

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

✨ Onyx Summary A new Harris Poll survey commissioned by ImmunityBio finds that most U.S. patients with non-muscle invasive bladder cancer receive limited discussion of treatment options despite heavy reliance on healthcare providers for guidance, and many seek alternatives to chemotherapy, including immunotherapy. The results underscore a communication gap in